×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
DSNKY – daiichi sankyo s/adr (US:AMEX)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
DSNKY
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
12/18
02:30 am
dsnky
DATROWAY® Type II Variation Application Validated in the EU as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who are Not Candidates for Immunotherapy
Low
Report
DATROWAY® Type II Variation Application Validated in the EU as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who are Not Candidates for Immunotherapy
12/16
05:40 am
dsnky
Daiichi Sankyo Company, Limited (DSNKY) Discusses Oncology Pipeline Advances and Phase III Clinical Updates at Science and Technology Day Transcript [Seeking Alpha]
Low
Report
Daiichi Sankyo Company, Limited (DSNKY) Discusses Oncology Pipeline Advances and Phase III Clinical Updates at Science and Technology Day Transcript [Seeking Alpha]
12/15
03:29 pm
dsnky
Roche receives FDA approval for first diagnostic tests to identify HER2-positive metastatic breast cancer patients eligible for ENHERTU [Yahoo! Finance]
Low
Report
Roche receives FDA approval for first diagnostic tests to identify HER2-positive metastatic breast cancer patients eligible for ENHERTU [Yahoo! Finance]
12/15
02:44 pm
dsnky
ENHERTU® Plus Pertuzumab Approved in the U.S. as First New Treatment in More Than a Decade for First-Line Treatment of Patients with HER2 Positive Metastatic Breast Cancer [Yahoo! Finance]
Neutral
Report
ENHERTU® Plus Pertuzumab Approved in the U.S. as First New Treatment in More Than a Decade for First-Line Treatment of Patients with HER2 Positive Metastatic Breast Cancer [Yahoo! Finance]
12/15
02:30 pm
dsnky
ENHERTU® Plus Pertuzumab Approved in the U.S. as First New Treatment in More Than a Decade for First-Line Treatment of Patients with HER2 Positive Metastatic Breast Cancer
Low
Report
ENHERTU® Plus Pertuzumab Approved in the U.S. as First New Treatment in More Than a Decade for First-Line Treatment of Patients with HER2 Positive Metastatic Breast Cancer
12/15
09:14 am
dsnky
Lunit Announces Collaboration with Daiichi Sankyo to Advance AI-Driven Biomarker Discovery and Translational Oncology Research [Yahoo! Finance]
Low
Report
Lunit Announces Collaboration with Daiichi Sankyo to Advance AI-Driven Biomarker Discovery and Translational Oncology Research [Yahoo! Finance]
12/15
09:00 am
dsnky
Lunit Announces Collaboration with Daiichi Sankyo to Advance AI-Driven Biomarker Discovery and Translational Oncology Research
Low
Report
Lunit Announces Collaboration with Daiichi Sankyo to Advance AI-Driven Biomarker Discovery and Translational Oncology Research
12/9
07:00 am
dsnky
DESTINY-Ovarian01 Phase 3 Trial of ENHERTU® Initiated as First-Line Maintenance Therapy in Patients with HER2 Expressing Advanced Ovarian Cancer
Low
Report
DESTINY-Ovarian01 Phase 3 Trial of ENHERTU® Initiated as First-Line Maintenance Therapy in Patients with HER2 Expressing Advanced Ovarian Cancer
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
7/31
Q1/2019 6/30/2019 EPS 66.770 ZacksConsensus N/A ActVsEst N/A - N/A
7.6%
7/31 Q1/2019 6/30/2019 EPS 66.770 ZacksConsensus N/A ActVsEst N/A - N/A 1.9%
5/8 AstraZeneca-Daiichi Sankyo breast cancer drug shows promise [Reuters] 1.8%
12/20 AstraZeneca, Daiichi's breast cancer drug gets accelerated approval from FDA [Reuters] 0.9%
12/11 AstraZeneca-Daiichi drug halts cancer for months in first readout [Reuters] 0.9%
5/14 FDA advisory panel votes against Daiichi Sankyo's blood cancer treatment [Reuters (UK)] 0.7%
2/11 Daiichi Sankyo Is Not A Buy Now [Seeking Alpha] 0.7%
8/2 UPDATE 1-U.S. FDA approves Daiichi Sankyo's treatment for rare joint tumor [Reuters] 0.5%
8/1 Q1/2019 6/30/2019 EPS 66.770 ZacksConsensus N/A ActVsEst N/A - N/A 0.5%
8/29 Positive Results Highlight Potential of Bempedoic Acid / Ezetimibe Combination for Hypercholesterolaemia with Type 2 Diabetes 0.4%
7/31 Q1/2019 6/30/2019 EPS 66.770 ZacksConsensus N/A ActVsEst N/A - N/A 1.9%
5/8 AstraZeneca-Daiichi Sankyo breast cancer drug shows promise [Reuters] 1.8%
12/20 AstraZeneca, Daiichi's breast cancer drug gets accelerated approval from FDA [Reuters] 0.9%
12/11 AstraZeneca-Daiichi drug halts cancer for months in first readout [Reuters] 0.9%
5/14 FDA advisory panel votes against Daiichi Sankyo's blood cancer treatment [Reuters (UK)] 0.7%
2/11 Daiichi Sankyo Is Not A Buy Now [Seeking Alpha] 0.7%
8/2 UPDATE 1-U.S. FDA approves Daiichi Sankyo's treatment for rare joint tumor [Reuters] 0.5%
8/1 Q1/2019 6/30/2019 EPS 66.770 ZacksConsensus N/A ActVsEst N/A - N/A 0.5%
8/29 Positive Results Highlight Potential of Bempedoic Acid / Ezetimibe Combination for Hypercholesterolaemia with Type 2 Diabetes 0.4%
TOP News Decliners
12/17
Japan shares edge lower on lacklustre export data, profit-taking [Reuters]
-5.4%
6/21 FDA declines to approve Daiichi Sankyo's blood cancer treatment [Reuters] -4.6%
4/1 Concert Pharma outlines late-stage CTP-543 trials in Alopecia Areata [Seeking Alpha] -2.7%
12/9 DAIICHI SANKYO/S (OTCMKTS: DSNKY) is now covered by analysts at Jefferies Financial Group Inc. They set a "buy" rating on the stock. -2.6%
2/20 Esperion's Multiple Positives, And Other News: The Good, Bad And Ugly Of Biopharma [Seeking Alpha] -1.5%
8/12 Daiichi Sankyo, Inc. Appoints Simon King as Chief People Officer across U.S. Divisions -1.1%
1/27 Phase 2 DESTINY-Gastric01 Trial of DS-8201 Versus Chemotherapy Met Primary Endpoint -1.0%
5/14 Precision NanoSystems Signs License Agreement with Daiichi Sankyo for Use of the NanoAssemblr GMP System for Development and Manufacture of Nanomedicines [Canadian Business Journal (Canada)] -0.4%
6/13 Dr. Nicole Saphier: Why Biden's vow to 'cure cancer' if elected received so much backlash [FOX News] -0.3%
8/2 U.S. FDA approves Daiichi Sankyo's treatment for rare joint tumor [Reuters (UK)] -0.3%
6/21 FDA declines to approve Daiichi Sankyo's blood cancer treatment [Reuters] -4.6%
4/1 Concert Pharma outlines late-stage CTP-543 trials in Alopecia Areata [Seeking Alpha] -2.7%
12/9 DAIICHI SANKYO/S (OTCMKTS: DSNKY) is now covered by analysts at Jefferies Financial Group Inc. They set a "buy" rating on the stock. -2.6%
2/20 Esperion's Multiple Positives, And Other News: The Good, Bad And Ugly Of Biopharma [Seeking Alpha] -1.5%
8/12 Daiichi Sankyo, Inc. Appoints Simon King as Chief People Officer across U.S. Divisions -1.1%
1/27 Phase 2 DESTINY-Gastric01 Trial of DS-8201 Versus Chemotherapy Met Primary Endpoint -1.0%
5/14 Precision NanoSystems Signs License Agreement with Daiichi Sankyo for Use of the NanoAssemblr GMP System for Development and Manufacture of Nanomedicines [Canadian Business Journal (Canada)] -0.4%
6/13 Dr. Nicole Saphier: Why Biden's vow to 'cure cancer' if elected received so much backlash [FOX News] -0.3%
8/2 U.S. FDA approves Daiichi Sankyo's treatment for rare joint tumor [Reuters (UK)] -0.3%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: